Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

NewsGuard 100/100 Score

Ipsen (Paris:IPN)(Euronext: IPN; ADR: IPSEY) today announced positive initial results from the double-blind phase III study of Dysport® (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport® showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale (MAS). In addition, a statistically significant clinical benefit for the patients treated with Dysport® was demonstrated versus placebo, as measured by the Physician Global Assessment (PGA). The safety profile observed in the study was consistent with the known safety profile of Dysport® in this indication. Comprehensive results from this double-blind study will be disclosed in the next few months at major international congresses.

Marc de Garidel, Chairman and CEO of Ipsen stated: "These clinical results are an important step in our ambition to become a global leader in the treatment of targeted debilitating diseases. Expanding our scope of indications for Dysport® would help us further develop the neurology franchise, notably in the USA."

Claude Bertrand, Executive Vice-President Research & Development and Chief Scientific Officer of Ipsen commented: "Ipsen is very pleased with the initial results of the Dysport® study in Adult Upper Limb spasticity. We believe it should meet the expectations of physicians by potentially providing a new alternative for treating patients suffering from this debilitating condition. We are grateful to the clinicians, caregivers, patients and their families who were involved in this study."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New sleep-enhancing nutraceutical blend falls short in clinical trial